Evidence map›Paper›PMID 27409665›Full record

SynthesisOncotarget2016

Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer.

Xiaobin Gu, Xian-Shu Gao, Ming Cui, Mu Xie, Chuan Peng, Yun Bai, Wei Guo, Linjun Han, Xiaodong Gu, Wei Xiong

Open access · diamondAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 11 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 11 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Dynamic Changes in Pre- and Postoperative Levels of Inflammatory Markers and Their Effects on the Prognosis of Patients with Gastric Cancer.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Xiaobin GuDepartment of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Xian-Shu GaoDepartment of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Ming CuiDepartment of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Mu XieDepartment of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Chuan PengDepartment of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Yun BaiDepartment of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Wei GuoGraduate School of Medicine, Hebei North University, Zhangjiakou, Hebei, China.
Linjun HanGraduate School of Medicine, Hebei North University, Zhangjiakou, Hebei, China.
Xiaodong GuDepartment of Breast Cancer Radiotherapy, Tumor Hospital of Shanxi Provence, Taiyuan, China.
Wei XiongDepartment of Oncology, Tangshan People's Hospital, Hebei, China.
Peking University First Hospital · CNHebei North University · CNPeking University · CNShanxi Provincial Cancer Hospital · CNTangshan People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study was aim to investigate the prognostic role of platelet to lymphocyte ratio (PLR) for patients with gastric cancer (GC) using meta-analysis. A total of 13 studies (14 cohorts) with 6,280 subjects were included. By pooling hazard ratios (HRs) and 95% confidence intervals (CIs) and odds ratios (ORs) and 95% CIs from each study, we found that elevated PLR was significantly associated with poorer overall survival (OS) (HR: 1.3, 95% CI: 1.1-1.52, p = 0.001; Ι² = 68.5%, Ph < 0.001) but not with poor disease-free survival (DFS) (HR: 1.6, 95% CI: 0.88-2.9, p = 0.122; I2 = 87.8%, Ph < 0.001). Subgroup analysis showed that a high PLR significantly predicted poor OS in Caucasian populations, patients receiving chemotherapy and patients at advanced stage. In addition, the cut-off value of PLR > 160 showed adequately prognostic value. Furthermore, elevated PLR was associated with lymph node metastasis and CEA levels in GC. Our meta-analysis showed that elevated PLR could be a significant prognostic biomarker for poor OS in patients with GC.

Indexed as

Antineoplastic AgentsBiomarkers, TumorBlood PlateletsCohort StudiesDisease-Free SurvivalHumansLymphocyte CountLymphocytesOdds RatioPlatelet CountPrognosisProportional Hazards ModelsStomach NeoplasmsTreatment OutcomeAntineoplastic AgentsBiomarkers, Tumorbiomarkergastric cancermeta-analysisPLRprognosis

Identifiers

PMID27409665
PMCPMC5226554
OpenAlexW2462139958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.